web analytics

A Next-Generation mRNA Vaccine Platform For Enhancing T-Cell Responses And Improving Antiviral And Antitumor Immunity

Published:
Lead Inventor: Jun Huang
Print or Save to PDF

SUMMARY

Next-generation mRNA vaccine platform uses a lipid-polymer hybrid nanoparticle to boost stability, immune cell uptake, and T cell responses, leading to stronger and longer-lasting protection against viruses and cancer while maintaining strong antibody responses

The Unmet Need: Intracellular delivery of mRNA to antigen-presenting cells while ensuring stability, controlled release, and effective lymph node targeting

  • Current mRNA vaccine platforms predominantly utilize lipid nanoparticle (LNP) formulations to encapsulate and deliver mRNA. While these systems have demonstrated safety and effectiveness, they face several limitations. Traditional LNPs can exhibit suboptimal stability, leading to premature degradation or inefficient delivery of mRNA to target cells. Additionally, their uptake by APCs such as dendritic cells and macrophages is often limited, resulting in transient antigen expression and insufficient activation of cytotoxic T lymphocytes. This can compromise the magnitude and duration of the immune response, particularly in the context of diseases that require strong cellular immunity, such as chronic viral infections and cancer.
  • Furthermore, conventional LNPs may not efficiently target lymph nodes, where immune responses are orchestrated, and may elicit only modest pro-inflammatory cytokine production, further limiting their immunostimulatory capacity. These shortcomings underscore the need for advanced delivery systems that can overcome the barriers of stability, targeting, and immune activation inherent in current mRNA vaccine technologies.

The Proposed Solution: Advanced mRNA vaccine platform employing a lipid-polymer hybrid nanoparticle promoting persistent intracellular mRNA expression, superior antigen presentation, and antigen-specific CD8+ T cell activation

  • The faculty inventor developed a next-generation mRNA vaccine platform utilizing a lipid-polymer hybrid nanoparticle formulation to significantly enhance immune responses. This structure improves the uptake of the nanoparticles by antigen-presenting cells such as dendritic cells and macrophages, leading to more persistent and efficient intracellular expression of mRNA-encoded antigens. The platform has been tested with mRNA for SARS-CoV-2 spike, influenza hemagglutinin, and ovalbumin, demonstrating superior antigen-specific T cell activation, elevated pro-inflammatory cytokine production, and enhanced lymph node targeting compared to conventional lipid nanoparticle (LNP) vaccines.

  • What differentiates this technology is its ability to elicit both potent cellular and humoral immune responses through its unique nanoparticle design. The increased rigidity and stability of the hybrid nanoparticles enable more efficient delivery and sustained expression of mRNA antigens, which translates into stronger and longer-lasting activation of CD8+ T cells, including cytotoxic effector memory subsets.

ADVANTAGES

ADVANTAGES

  • Enhanced uptake and antigen presentation by antigen-presenting cells due to lipid-polymer hybrid nanoparticle formulation

  • Increased and sustained intracellular mRNA expression leading to stronger and longer-lasting immune responses

  • Significantly higher antigen-specific CD8+ T cell activation and pro-inflammatory cytokine production

  • Improved targeting and accumulation in lymph nodes for effective immune system activation

  • Maintains robust humoral immunity with strong antibody responses and virus neutralization

  • Demonstrated durable and protective immunity with tumor elimination and rejection upon re-challenge

APPLICATIONS

  • Therapeutic cancer vaccine
  • Personalized neoantigen vaccine
  • Drug delivery
  • Demonstrated effectiveness in both infectious disease and cancer preclinical models